文献速递主动脉疾病

水通道蛋白4:血管内胸腹主动脉瘤修复术后永久性截瘫的预测因子与治疗靶点

Editor's Choice - Aquaporin-4: A Predictor and Therapeutic Target for Permanent Paraplegia after Endovascular Thoraco-abdominal Aortic Aneurysm Repair.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2026-01-23

该研究对37例接受血管内胸腹主动脉瘤修复术的患者进行脑脊液蛋白质组学分析,发现永久性截瘫患者脑脊液中水通道蛋白4(AQP4)水平约为恢复者或未发生截瘫者的4倍(41.8 ± 19.2 ng/mL vs 10.8 ± 1.3 ng/mL,p = .005;vs 10.8 ± 1.2 ng/mL,p = .004),且AQP4>15 ng/mL与脊髓水肿加重相关(1.77 ± 0.19 vs 1.03 ± 0.36,p = .032)。在大鼠缺血性脊髓损伤模型中,抑制AQP4可保护脊髓神经元和胶质细胞(p = .004)并预防缺血诱导的截瘫(p < .001)。

要点

  • 脑脊液AQP4水平>15 ng/mL可预测胸腹主动脉瘤术后永久性截瘫。
  • 永久性截瘫患者脑脊液AQP4约为恢复者的4倍,且与脊髓水肿加重相关。
  • 大鼠模型中抑制AQP4可保护脊髓组织并预防缺血性截瘫。

核心结论

  • 脑脊液AQP4水平是胸腹主动脉瘤修复术后永久性截瘫的预后标志物。
  • AQP4抑制在缺血性脊髓损伤模型中显示出治疗潜力。

研究设计与样本

  • 前瞻性收集37例接受血管内胸腹主动脉瘤修复术患者的脑脊液进行蛋白质组学分析。
  • 患者中位年龄73.5岁(范围67-78岁),男性27例、女性10例;Crawford分型:I型6例、II型11例、III型15例、IV型3例、V型2例。
  • 所有患者均使用定制分支或开窗支架装置完成修复。
  • 采用串联质谱标签蛋白质组学分析脑脊液蛋白组成。
  • 在大鼠缺血性脊髓损伤模型中验证蛋白质组学发现的治疗靶点。

主要发现

  • 5例患者遗留永久性截瘫,7例从短暂性截瘫中恢复。
  • 永久性截瘫患者脑脊液AQP4为41.8 ± 19.2 ng/mL(n = 5),显著高于恢复者10.8 ± 1.3 ng/mL(n = 7;p = .005)和未发生截瘫者10.8 ± 1.2 ng/mL(n = 25;p = .004)。
  • 永久性截瘫患者脑脊液AQP4均>15 ng/mL,且与T2加权MRI上更严重的脊髓水肿相关(1.77 ± 0.19 vs 1.03 ± 0.36;p = .032)。
  • 大鼠缺血性脊髓损伤模型中,AQP4抑制保护了白质背角和中间区的脊髓神经元和胶质细胞(p = .004)。
  • 大鼠模型中AQP4抑制预防了缺血诱导的截瘫(p < .001)。

临床怎么用

  • 术后监测脑脊液AQP4水平可能有助于识别永久性截瘫高危患者。
  • AQP4抑制可能是缺血性脊髓损伤的潜在治疗策略,尚需临床验证。

局限性

  • 人类脑脊液分析样本量小(永久性截瘫仅5例),结论需更大样本验证。
  • AQP4抑制的治疗效果仅在大鼠模型中验证,尚未在人体中证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Endovascular thoraco-abdominal aortic aneurysm (TAAA) repair can impair spinal cord perfusion, leading to paraplegia. The mechanisms driving this devastating complication are poorly understood. This study aimed to interrogate the cerebrospinal fluid (CSF) proteome in patients after TAAA repair to identify biomarkers that herald permanent paraplegia. It also aimed to investigate a potential therapeutic target identified by proteomics using an in vivo model of ischaemic spinal cord injury (iSCI). METHODS: CSF was collected for proteomic analysis from patients before and following TAAA repair. A differentially expressed protein identified in human paraplegic subjects was subsequently interrogated in a rodent model of iSCI. The protein composition of CSF was analysed using tandem mass tag proteomics. Neurological examinations were carried out by a blinded neurologist and T2 weighted magnetic resonance imaging (MRI) was used to measure spinal cord volume and oedema. A rodent model of iSCI was used to investigate a clinically relevant therapeutic target informed by proteomic findings. RESULTS: CSF analysis was taken from 37 patients, all of whom had aneurysm repair using a custom branched and or fenestrated device (median age 73.5 years, range 67 - 78 years; 27 men, ten women; Crawford classification: six type I, 11 type II, 15 type III, three type IV, and two type V). Five patients remained permanently paraplegic and seven recovered from transient paraplegia. The CSF of patients who remained paraplegic contained approximately fourfold more aquaporin-4 (AQP4) (41.8 ± 19.2 ng/mL, n = 5) than those who recovered from paraplegia (10.8 ± 1.3 ng/mL, n = 7; p = .005) or did not develop paraplegia (10.8 ± 1.2 ng/mL, n = 25; p = .004). Permanently paraplegic patients had CSF AQP4 levels > 15 ng/mL and this was associated with greater cord oedema on T2 weighted MRI (1.77 ± 0.19 vs. 1.03 ± 0.36; p = .032). In a rodent model of iSCI, AQP4 inhibition preserved spinal neurons and glia in the dorsal horn and intermediate zones of white matter (p = .004) and protected against ischaemia induced paraplegia (p < .001). CONCLUSION: The AQP4 level in the CSF of a patient represents a prognostic marker of permanent paraplegia after TAAA repair and highlights a novel therapeutic target. These findings represent a conceptual advance in the management of iSCI.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Kelly JA, Salih M, Patel A, et al. Editor's Choice - Aquaporin-4: A Predictor and Therapeutic Target for Permanent Paraplegia after Endovascular Thoraco-abdominal Aortic Aneurysm Repair. Eur J Vasc Endovasc Surg. 2026. PMID: 41581749. doi:10.1016/j.ejvs.2026.01.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。